2002: GenOdyssee signed one out-licensing deal with Swiss Pharma Debiopharm (Lausanne, Switzerland)
2006: GenOdyssee signed one research collaboration with Baxter AG (Vienna, Austria)

GenOdyssee’s mission is to discover and develop superior variants of large and well addressed virology, immunotherapy, and hematology indications core protein drugs to address hard-to-treat patients and help the Industry develop further existing and profitable franchises in these indications.

Key competitive advantages

Interest in protein therapeutics in recent years has been strong and increasing in the industry. This is eventually due to the better success rate of this class of molecules as compared to new chemical entities. GenOdyssee believes that in this large and still growing market, improved protein therapeutic drugs (or so called biologicals) are the fastest and certainly lower risk way to pipelines’ renewal with new products and value. In this field, we believe that our unique technology backed by a strong and dominant intellectual property, is better positioned than others for the following reasons:

• Our products have a human and natural origin and present a minimal safety risk
• They show higher potency and/or safety, we then believe they can address medical needs left by first-generation drugs
• Our products address large market needs, starting with HCV genotype 1 relapsing or resistant patients and cancer
• They are intellectual property protected in up to 15 countries including the EU, the USA and emerging countries
• At last, because our technology can be extended to many new products in a large spectrum of therapeutic indications


Key partnership considerations